Scisparc Shares Drop 10% as FDA‑Approved Tourette Trial Accelerates
Scisparc Ltd. shares drop 10% as the company’s NeuroThera Labs Phase IIb trial for Tourette syndrome launches, sparking investor interest in its cannabinoid therapy.
2 minutes to read
